Genetic Engineering & Biotechnology News (GEN) has retained its position as the premier biotech publication since its launch in 1981. GEN publishes a print edition 21 times a year and has additional exclusive editorial content online, including news and analysis as well as webinars, videos, and poll…
Genetic Engineering and Biotechnology News
Hosted on Acast. See acast.com/privacy for more information.
As good scientific investigators, we strive to make our research more reproducible, repeatable, and translatable. These traits are ostensibly engrained in researchers from the start of their careers but often fall to the wayside in pursuit of experimental answers. Throughout this three-episode podcast series, sponsored by The Baker Company, we will weave the common thread of these essential research traits and discuss some ubiquitous techniques common to so many laboratories—focusing on areas that are often overlooked but can have a considerable impact on recapitulating physiological conditions and the efficacy of your experiments. So tune in to this first podcast where we discuss the importance of oxygen biology in common lab experiments. Hosted on Acast. See acast.com/privacy for more information.
Single-use systems have been steadily climbing toward the top of the tools utilized by biomanufacturers for the commercial-scale production of critical therapeutic products. However, COVID-19 created an inflection point for this technology, generating an even greater demand that will shape the market for many years. Yet, with considerable demand comes the need to focus on the key aspects driving growth while discovering the appropriate solutions to the challenges that invariably arise when technologies are being developed and utilized rapidly.This is our third and final episode of GENcast, where Dr. Ger Brophy, the Executive Vice President of Biopharma Production at Avantor, joins me. We sat down to discuss several essential facets of single-use systems and some ways to help manage risk and decrease the intricacies most often associated with single-use supply chains. Make sure you check out episode one and episode two for more in-depth discussions with Dr. Brophy. Hosted on Acast. See acast.com/privacy for more information.
The demand for safe and efficacious biologics has accelerated exponentially in the past several years due to the tremendous success of some of the initial therapeutic offerings in this space. Yet, along with this increased demand comes the need for innovative solutions to improve downstream production workflows. For example, eliminating purification bottlenecks and improving overall yields from chromatography steps can significantly impact the final product's cost.In this second episode of GENcast with Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, we dive into some of the challenges biomanufacturers face during downstream purification and how addressing the traditional thinking surrounding chromatography resins, and buffers can be highly advantageous and immensely cost-effective. Take a listen to episode 2 below, and if you want to check out episode 1, click here! Hosted on Acast. See acast.com/privacy for more information.
The success and applications of cell and gene therapies are seemingly limitless, and economic forecasts project a compound annual growth rate of almost 40% over the next eight years. This rapid expansion is a double edge sword for biomanufacturers of cell and gene therapy products. On the one hand, the tremendous growth is excellent for business. Yet, on the flip side, biomanufacturers are faced with solving the numerous challenges of scaling-up production workflows: from raw material sourcing to supply chain management to adopting new and innovative production modalities. Having a trusted global partner that can help organizations navigate the tumultuous bioprocessing waters of cell and gene therapy production is advantageous and often the key to continued success in the space.In this GENcast, we sit down with the Executive Vice President of Biopharma Production at Avantor, Dr. Ger Brophy, to discuss some of the precautions and improvements for cell and gene therapies and how manufacturers can address many of the challenges they face. Take a listen! Hosted on Acast. See acast.com/privacy for more information.
This is the final episode in our three-part GENcast series, where we discuss the virtues of mechanistic modeling and how it can significantly impact critical decision-making points in the drug discovery process, especially as drug developers move closer toward the IND process. In our two previous podcasts, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. You can listen to the earlier podcasts with the following links: episode 1, episode 2. In this latest GENcast, I met up once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to discuss the specific applications of mechanistic modeling, especially concerning the process of deciding the first human dose numbers, and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See acast.com/privacy for more information.
This is part two in our three-part GENcast series, where we discuss various aspects of the drug discovery and development process and, in particular, how advanced computational techniques like mechanistic modeling can help advance the therapeutic drug pipeline for many developers. In our initial podcast, we were introduced to mechanistic modeling concepts and the basics of how they can be applied to drug discovery workflows. In this latest GENcast, I sat down once again with Dr. John Burke, President, CEO, and Co-founder of Applied BioMath, to take a deeper dive into the specific applications of mechanistic modeling and how his company is helping biotech and pharma organizations reduce their late-stage drug attrition rates. Take a listen! Hosted on Acast. See acast.com/privacy for more information.
The drug discovery and development process can be an arduous endeavor. Manufacturers spend considerable resources and money chasing down potential candidate molecules to create a potential new therapeutic—often resulting in abandoning the candidate in the very later stages of development due to minor factors that might have been overlooked at the onset of the discovery process. Thankfully, there have always been those investigators who sought to merge the fields of mathematics and biology while taking advantage of advanced computing algorithms to help inform and de-risk drug discovery decisions and streamline the development pipeline. This mechanistic modeling approach is helping to transform drug R&D projects by giving pharma and biotech companies the vital information they need to make the critical decisions in a drug's path toward clinical success.In this GENcast, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully. Jump into the discussion and take a listen! See acast.com/privacy for privacy and opt-out information.
GEN Biotechnology is the new peer-reviewed journal launching in early 2022 by Mary Ann Liebert Inc. aiming to publish outstanding original research and perspectives across the biotech field. In this Q&A, GEN Biotechnology Senior Editor, Fay Lin, PhD, interviews Editor-in-Chief, Hana El-Samad, PhD, about her scientific research, outreach, and vision for the journal. Learn more about GEN Biotechnology: Website: www.genbiotechjournal.comTwitter: @GENBiotechJrnlSend editorial inquiries to editor@genbiotechjournal.com See acast.com/privacy for privacy and opt-out information.
See acast.com/privacy for privacy and opt-out information.
Navigating the Regulatory Terrain during Cell & Gene Therapy Production by Genetic Engineering and Biotechnology News See acast.com/privacy for privacy and opt-out information.
Solve Your Biotherapeutic Challenges with Help from Gene Therapy University by Genetic Engineering and Biotechnology News
Engineered Therapy: Ramping Up CAR-T Biomanufacturing Goals by Genetic Engineering and Biotechnology News
Gretchen Kusek, PhD, Associate Director Scientific Services, and Bart Smits, PhD, Manager Genetic Sciences and Compliance, discuss the key considerations when breeding gene-edited animals using CRISPR, particularly in the context of mosaicism.
Collaborating for Filtration Success, Virtually by Genetic Engineering and Biotechnology News
Back to the Lab – Embracing Change by Genetic Engineering and Biotechnology News
Virtual Becomes Reality for Biopharma Vaccine Development by Genetic Engineering and Biotechnology News
Digital Tools Push Single-Use Technology Challenges to the Side by Genetic Engineering and Biotechnology News
The Quiet Voice of Immunotherapy That's Starting to Be Heard by Genetic Engineering and Biotechnology News
With regions of the world cycling through societal re-openings and shutdowns due to the ongoing coronavirus pandemic, pharma and life science companies are tasked with trying to find creative solutions that help keep production lines moving, as well as drive innovation forward. For instance, pharmaceutical manufacturers still need to meet critical project timelines so that patients receive the therapies they require. As such, many companies require varying levels of technical support to accomplish their goals—a scenario made much more difficult due to travel and in-person meeting restrictions. Thankfully, the resilient team at the M Lab™ Collaboration Centers from MilliporeSigma were able to work out virtual solutions to support their partner Vuab Pharma reach their manufacturing goals. Take a listen to this latest GENcast and see how the virtual world stepped up to help the pharma space.
David Sorrell, PhD, from Horizon Discovery, speaks with GEN about the importance of cell models in the drug discovery process.
GENcast: CRISPR Screens Speed Drug Discovery Efforts for Disease Intervention by Genetic Engineering and Biotechnology News
Impact of COVID-19 on the Life Sciences Industry by Genetic Engineering and Biotechnology News
Trends in Bioprocess 4.0 and their Impact on Biomanufacturing by Genetic Engineering and Biotechnology News
GENcast: Navigating Your Lab through a Digital Transformation by Genetic Engineering and Biotechnology News
Helping Biosimilars Emerge into Global Markets Takes a Practiced Hand by Genetic Engineering and Biotechnology News
Filtration, filtration, filtration! It’s one of the critical factors to instituting a successful biomanufacturing process and often the element that gives scientists and engineers the most difficulty. Late-stage bioprocesses often require large volume manufacturing to meet supply requirements, and these increased volumes create challenging filtration operations—disrupting facility fit. Because so much is at stake for companies to generate bioproducts in short timeframes, when faced with these types of bioproduction challenges, organizations will waste valuable time and resources on developing creative solutions, in addition to making undesirable capital purchases. In this GENcast, we explore different troubleshooting techniques that the M Lab™ Collaboration Center experts employed, together with Biogen, to solve their facility fit challenges.
Filtration, filtration, filtration! It’s one of the critical factors to instituting a successful biomanufacturing process and often the element that gives scientists and engineers the most difficulty. Late-stage bioprocesses often require large volume manufacturing to meet supply requirements, and these increased volumes create challenging filtration operations—disrupting facility fit. Because so much is at stake for companies to generate bioproducts in short timeframes, when faced with these types of bioproduction challenges, organizations will waste valuable time and resources on developing creative solutions, in addition to making undesirable capital purchases. In this GENcast, we explore different troubleshooting techniques that the M Lab™ Collaboration Center experts employed, together with Biogen, to solve their facility fit challenges.
While the idea of a magic bullet that treats all maladies is a concept grounded in antiquity, antibody drug conjugates (ADCs) get a lot closer than almost any other class of drugs. The coupling of broadly cytotoxic compounds to the precision targeting of monoclonal antibodies creates a therapeutic weapon of disease destruction. Yet, as with most biotherapeutic manufacturing processes, scaling-up these compounds efficiently is never straight forward. Still, with the global ADC market proliferating, scientists and engineers are looking for the best path forward to address their bioprocessing challenges. In this GENcast, we hear from a panel of ADC experts about how they have addressed some of the most challenging aspects of manufacturing these complex therapeutics and how they are reading the current ADC manufacturing terrain.
While the idea of a magic bullet that treats all maladies is a concept grounded in antiquity, antibody drug conjugates (ADCs) get a lot closer than almost any other class of drugs. The coupling of broadly cytotoxic compounds to the precision targeting of monoclonal antibodies creates a therapeutic weapon of disease destruction. Yet, as with most biotherapeutic manufacturing processes, scaling-up these compounds efficiently is never straight forward. Still, with the global ADC market proliferating, scientists and engineers are looking for the best path forward to address their bioprocessing challenges. In this GENcast, we hear from a panel of ADC experts about how they have addressed some of the most challenging aspects of manufacturing these complex therapeutics and how they are reading the current ADC manufacturing terrain.
GENcast: Welcoming a Digital Revolution in Life Science by Genetic Engineering and Biotechnology News
Positive global health outcomes are often contingent on more than just great science, as knowledge sharing is also a fundamental part of achieving public health goals. With drug resistance on the rise for many pathogens once thought well managed clinically, scientists are looking toward the development of new vaccines to help reduce morbidity and mortality for many global diseases. Collaboration between academia, industry, suppliers, and government organizations is crucial for the successful development of these vaccines, as these intellectual exchanges help accelerate production timelines, reduce costs, and increase chances of bringing an essential vaccine to market. The experts from the M Lab™ Collaboration Centers at Merck are no strangers to knowledge sharing and have been involved in supporting a number of successful vaccine development projects. In this GENcast, we talk to a diverse group of public health scientists and discuss their vaccine development projects and how the M Lab Collaboration Centers were able to assist them toward positive outcomes.
Positive global health outcomes are often contingent on more than just great science, as knowledge sharing is also a fundamental part of achieving public health goals. With drug resistance on the rise for many pathogens once thought well managed clinically, scientists are looking toward the development of new vaccines to help reduce morbidity and mortality for many global diseases. Collaboration between academia, industry, suppliers, and government organizations is crucial for the successful development of these vaccines, as these intellectual exchanges help accelerate production timelines, reduce costs, and increase chances of bringing an essential vaccine to market. The experts from the M Lab™ Collaboration Centers at MilliporeSigma are no strangers to knowledge sharing and have been involved in supporting a number of successful vaccine development projects. In this GENcast, we talk to a diverse group of public health scientists and discuss their vaccine development projects and how the M Lab Collaboration Centers were able to assist them toward positive outcomes.
GENcast Explore, Learn, & Collaborate On Viral Safety In Biomanufacturing by Genetic Engineering and Biotechnology News
Great symphonic music starts with the fundamental elements common to all orchestral instruments, but what separates a good symphony from a great one is not just pure talent, but the ability of the musicians to work together to create something ethereal. In most respects, science is no different. The open exchange of ideas and collaborative spirit is how science moves forward to create something impactful for society. And like great instrumentalists, scientists practice their craft every time they step into the laboratory—but even the most talented amongst them requires assistance on occasion. The need for these collaborative scientific environments is most apparent in emerging biotechnology regions like China, where companies are quickly ramping up biomanufacturing processes to become competitive with more established biotech hubs. Scientists at the M Lab™ Collaboration Centers from MilliporeSigma are well versed in supporting scientists and engineers and assisting them with bioprocessing challenges that can make even the most harmonious scientific teams go out of tune. They M Lab Collaboration Centers’ team has the expertise to assist growing companies with manufacturing scale-up questions, provide chromatography support, and offer the latest expertise on single-use bioprocessing systems. We connected recently with a few members of the M Lab Collaboration Centers to discuss some of the recent, successful projects they collaborated on with clients in China. They discuss some of the challenges they faced on their project, how they set out to resolve those issues, and what the future holds for them and the Chinese biopharma market. Listen in to the conversation below.
Empowering a Precision Health Movement with Kevin Hrusovsky by Genetic Engineering and Biotechnology News
GENcast Explore, Learn, & Collaborate As Next-Generation Bioprocessing Moves Toward Future Horizons by Genetic Engineering and Biotechnology News
GENcast Interview with Quanterix CEO Kevin Hrusovsky by Genetic Engineering and Biotechnology News
Nanostring Podcast with David Rimm, MD, PhD by Genetic Engineering and Biotechnology News
ATCC Podcast Final by Genetic Engineering and Biotechnology News
GENcast: Explore, Learn, and Collaborate on Regulatory Challenges in Asia by Genetic Engineering and Biotechnology News
GENcast: Explore, Learn, and Collaborate on Cell & Gene Therapy Manufacturing Challenges by Genetic Engineering and Biotechnology News
They say, “good talent is hard to find!” This is especially true for emerging high-growth markets where many in the workforce lack the advanced skills necessary to aid their bioproduction needs and expand their market profile. Leveraging the success of the M Lab™ Collaboration Centers, the MilliporeSigma team was able to foster key collaborations with government agencies to provide essential hands-on training programs in various Asia-Pacific countries such as Singapore and Taiwan. In this podcast, we will hear from the individuals that were integral to launching these vital initiatives. Chii-Wann Lin, PhD Vice President and General Director of Biomedical Technology and Device Research Laboratories, and Industrial Technology Research Institute (ITRI). Chin Bin Tan, Head of Technology Management, APAC, MilliporeSigma. This is part two in the five-part podcast series tackling diverse issues such as the need for speed to market in gene therapy, next-generation bioprocessing, and viral safety assurance in upstream and downstream. Make sure you check back regularly to hear the latest GENcast session.
GENcast: Explore, Learn, and Collaborate on Next-Generation Bioprocessing As biomolecules become increasingly complex and manufacturer pipelines more diversified, scientists are searching for new ways to overcome the challenges of rapidly changing bioprocessing platforms. In this podcast, we have gathered an array of industry experts to discuss their efforts with the M Lab™ Collaboration Centers around the globe to address some of the latest developments in Next-Generation Bioprocessing. This is the first in a five-part podcast series tackling diverse issues such as the need for speed to market in gene therapy, the demand for personnel training in emerging markets, and viral safety assurance in upstream and downstream. So, make sure you check back regularly to hear the latest GENcast session. Panelists: Torsten Bisschop, Karen Chan, Matteo Costioli, PhD, Mike Felo, and Emily Peterson https://www.genengnews.com/resources/podcasts/gencast/next-gen-bioprocessing-millipore/
GEN Sounds of Science November 5, 2018 Illumina just purchased Pacific BioSciences (PacBio) for $1.2 billion. Shawn Baker formerly worked for Illumina as both a scientist and manager. He currently serves as the chief science officer for AllSeq and as a genomics startup advisor and consultant at SanDiegOmics.com. GEN asked Shawn about the significance of Illumina buying PacBio to the sequencing market and to obtain his take on what’s driving the Illumina deal?
GEN Sounds of Science June 1, 2018 CEM Corporation Applies Advanced Microwave Technology CEM provides microwave instrumentation for researchers involved in analytical and synthetic chemistry. Major application areas include acid digestion for elemental analysis, compositional testing of food products, peptide synthesis, and chemical synthesis. GEN recently spoke to Michael J. Karney, CEM’s life science product manager. During a sponsored pocast, Mr. Karney described how CEM’s technologies are improving workflows for end users, specifically in the fields of drug design and development.
GEN Sounds of Science May 1, 2018 GEN recently spoke to Minjun Liu, Ph.D., marketing director for OriGene, for a sponsored podcast. OriGene Technologies was founded as a research tool company focused on the creation of a large commercial collection of full-length human cDNAs in a standard expression vector. Company officials say the firm’s mission is to prepare comprehensive, genome-wide research tools and technology platforms to allow scientists to better study complete biological pathways. The goal is to enable more detailed insights into stem-cell research and into disease mechanisms, such as those that lead to cancer.
GEN Sounds of Science January 26, 2018 Technology and Data Usher in a New Age in Medicine Having the right data and knowing how to use it will be the key to success in the healthcare market in the future.
GEN Sounds of Science November 29, 2017 Canadian team identifies protein that when hindered decreases invasion rate of cancer cells.
GEN Sounds of Science October 23, 2017 Researchers discovered that corneal cells isolated from human donors and grown on a dome-shaped surface behaved differently than those on flat one. There are a number of advantages to using such curved substrates.
GEN Sounds of Science September 15, 2017 MilliporeSigma is using is expertise in biomanufacturing to take advantage of the growing interest in continuous or next generation bioprocessing. The company is investing in specific technologies in terms of dedicated teams, focused R&D efforts, and product-development projects. Website: http://www.emdmillipore.com/
© 2020-2025 Ivy Podcast Discovery LLC
